• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统性炎症标志物与局部晚期食管胃交界腺癌患者的预后。

Systemic inflammatory markers and outcome in patients with locally advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.

机构信息

Northern Oesophago-Gastric Cancer Unit, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.

Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

出版信息

Br J Surg. 2017 Mar;104(4):401-407. doi: 10.1002/bjs.10425. Epub 2017 Jan 10.

DOI:10.1002/bjs.10425
PMID:28072456
Abstract

BACKGROUND

Raised levels of systemic inflammatory markers are associated with poor survival in patients with cancer. The aim of this study was to assess the prognostic value of markers of systemic inflammation in patients with adenocarcinoma of the oesophagus or gastro-oesophageal junction.

METHODS

Data from a consecutive series of patients undergoing transthoracic oesophagectomy following neoadjuvant therapy at a single centre were analysed. Fibrinogen, albumin, C-reactive protein, leucocyte differential and platelet counts were measured before surgery. The upper quartile (75th percentile) was used as a cut-off for dichotomization. Multivariable regression analysis was performed to identify independent prognostic factors.

RESULTS

A series of 199 patients underwent transthoracic oesophagectomy following neoadjuvant therapy. Univariable analysis indicated that reduced median survival was associated with a raised platelet : lymphocyte ratio (158 or above; 25.6 versus 44·4 months for patients with a normal ratio, P = 0·038) and increased fibrinogen levels (4·9 g/l or above; 22·8 versus 59·9 months for those with a normal level, P = 0·005). On multivariable analysis a combination of one or more markers of systemic inflammation was associated with poorer overall survival (hazard ratio 2·12, 95 per cent c.i. 1·20 to 3·74; P = 0·010).

CONCLUSION

Preoperative markers of systemic inflammation predict poor outcome in patients undergoing curative treatment for locally advanced oesophageal and gastro-oesophageal adenocarcinoma.

摘要

背景

全身性炎症标志物水平升高与癌症患者的生存不良有关。本研究旨在评估全身炎症标志物在食管或胃食管交界处腺癌患者中的预后价值。

方法

对单中心接受新辅助治疗后行经胸食管切除术的连续患者系列数据进行了分析。手术前测量纤维蛋白原、白蛋白、C 反应蛋白、白细胞分类计数和血小板计数。使用四分位数(第 75 个百分位数)作为二分类的截断值。进行多变量回归分析以确定独立的预后因素。

结果

199 例患者接受了新辅助治疗后经胸食管切除术。单变量分析表明,血小板与淋巴细胞比值升高(158 或以上;正常比值患者的中位生存期为 25.6 个月,而比值升高患者为 44.4 个月,P=0.038)和纤维蛋白原水平升高(4.9 g/l 或以上;正常水平患者的中位生存期为 22.8 个月,而升高患者为 59.9 个月,P=0.005)与降低的中位生存期相关。多变量分析显示,一种或多种全身炎症标志物的组合与总体生存较差相关(风险比 2.12,95%置信区间 1.20 至 3.74;P=0.010)。

结论

术前全身炎症标志物可预测接受局部晚期食管和胃食管交界处腺癌根治性治疗患者的预后不良。

相似文献

1
Systemic inflammatory markers and outcome in patients with locally advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.系统性炎症标志物与局部晚期食管胃交界腺癌患者的预后。
Br J Surg. 2017 Mar;104(4):401-407. doi: 10.1002/bjs.10425. Epub 2017 Jan 10.
2
Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy.新辅助治疗和食管切除术后淋巴结外侵犯的预后影响。
Br J Surg. 2016 Nov;103(12):1658-1664. doi: 10.1002/bjs.10226. Epub 2016 Oct 3.
3
Prognostic nomogram for patients undergoing oesophagectomy for adenocarcinoma of the oesophagus or gastro-oesophageal junction.接受食管癌或胃食管交界腺癌食管切除术患者的预后列线图
Br J Surg. 2007 Nov;94(11):1361-8. doi: 10.1002/bjs.5832.
4
Outcome of oesophagectomy for adenocarcinoma of the oesophagus and oesophagogastric junction.食管及食管胃交界腺癌的食管切除术结果
ANZ J Surg. 2005 Jul;75(7):513-9. doi: 10.1111/j.1445-2197.2005.03433.x.
5
Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.新辅助化疗后的肿瘤分期决定了食管和食管胃交界腺癌手术后的生存情况。
J Clin Oncol. 2014 Sep 20;32(27):2983-90. doi: 10.1200/JCO.2014.55.9070.
6
Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.食管癌和胃食管交界部癌手术后的发病率和死亡率:新辅助化疗与新辅助放化疗的随机临床试验
Eur J Surg Oncol. 2015 Jul;41(7):920-6. doi: 10.1016/j.ejso.2015.03.226. Epub 2015 Apr 8.
7
Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.局部晚期胃食管结合部腺癌新辅助放化疗或化疗后的预后。
Br J Surg. 2021 Nov 11;108(11):1332-1340. doi: 10.1093/bjs/znab228.
8
Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer.比较肿瘤相关因素和患者相关因素在接受食管癌根治性切除患者中的预后价值。
World J Surg. 2011 Aug;35(8):1861-6. doi: 10.1007/s00268-011-1130-7.
9
Surgical approach and results of surgery in adenocarcinoma of the gastro-oesophageal junction.胃食管交界腺癌的手术入路及手术结果
Singapore Med J. 2000 Jan;41(1):14-8.
10
Comparative Investigation of Postoperative Complications in Patients With Gastroesophageal Junction Cancer Treated With Preoperative Chemotherapy or Surgery Alone.术前化疗或单纯手术治疗的胃食管交界癌患者术后并发症的对比研究
Scand J Surg. 2016 Mar;105(1):22-8. doi: 10.1177/1457496915577021. Epub 2015 Mar 20.

引用本文的文献

1
Early prediction of postoperative infection using inflammatory markers after cytoreductive surgery for peritoneal carcinomatosis.腹膜癌减瘤手术后使用炎症标志物对术后感染进行早期预测。
World J Gastrointest Surg. 2025 May 27;17(5):101323. doi: 10.4240/wjgs.v17.i5.101323.
2
Analysis of the safety and efficacy of laparoscopic gastrojejunostomy following neoadjuvant chemotherapy for gastric pyloric obstruction.新辅助化疗后腹腔镜胃空肠吻合术治疗幽门梗阻的安全性和有效性分析
Front Oncol. 2025 Mar 18;15:1430761. doi: 10.3389/fonc.2025.1430761. eCollection 2025.
3
Elevated fibrinogen-albumin ratio is an adverse prognostic factor for patients with primarily resected gastroesophageal adenocarcinoma.
纤维蛋白原-白蛋白比值升高是原发性胃食管腺癌切除术后患者的不良预后因素。
J Cancer Res Clin Oncol. 2024 Oct 14;150(10):459. doi: 10.1007/s00432-024-05976-z.
4
Clinical implications of CT-detected ascites in gastric cancer: association with peritoneal metastasis and systemic inflammatory response.CT检测到的胃癌腹水的临床意义:与腹膜转移及全身炎症反应的关联
Insights Imaging. 2024 Oct 7;15(1):237. doi: 10.1186/s13244-024-01818-1.
5
Association of the systemic inflammation and anthropometric measurements with cancer risk: a prospective study in MJ cohort.全身炎症和人体测量指标与癌症风险的关联:MJ队列的前瞻性研究
Front Oncol. 2024 Sep 9;14:1400893. doi: 10.3389/fonc.2024.1400893. eCollection 2024.
6
Haematological and nutritional prognostic biomarkers for patients receiving CROSS or FLOT.接受CROSS或FLOT治疗患者的血液学和营养预后生物标志物。
J Gastrointest Oncol. 2023 Apr 29;14(2):494-503. doi: 10.21037/jgo-22-886. Epub 2023 Mar 16.
7
The prognostic utility of preoperative neutrophil-to-lymphocyte ratio (NLR) in patients with colorectal liver metastasis: a systematic review and meta-analysis.术前中性粒细胞与淋巴细胞比值(NLR)对结直肠癌肝转移患者的预后价值:一项系统评价和荟萃分析
Cancer Cell Int. 2023 Feb 28;23(1):39. doi: 10.1186/s12935-023-02876-z.
8
Combining nutritional status with TNM stage: a physiological update on gastric cancer staging for improving prognostic accuracy in elderly patients.将营养状况与 TNM 分期相结合:改善老年患者预后准确性的胃癌分期生理学更新。
Int J Clin Oncol. 2022 Dec;27(12):1849-1858. doi: 10.1007/s10147-022-02250-5. Epub 2022 Oct 18.
9
Benefit of a flash dose of corticosteroids in digestive surgical oncology: a multicenter, randomized, double blind, placebo-controlled trial (CORTIFRENCH).糖皮质激素冲击治疗在消化道肿瘤外科中的获益:一项多中心、随机、双盲、安慰剂对照研究(CORTIFRENCH)。
BMC Cancer. 2022 Aug 23;22(1):913. doi: 10.1186/s12885-022-09998-z.
10
Serum Anti-BRAT1 is a Common Molecular Biomarker for Gastrointestinal Cancers and Atherosclerosis.血清抗BRAT1是胃肠道癌症和动脉粥样硬化的常见分子生物标志物。
Front Oncol. 2022 May 17;12:870086. doi: 10.3389/fonc.2022.870086. eCollection 2022.